-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by Novartis at...
More »SEARCH RESULT
Total Matching Records found : 977
Landmark verdict -V Venkatesan
-Frontline The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving Drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...
More »Superior packaging can’t be used to raise prices: High Court to Sanofi SA -Maulik Vyas
-The Economic Times MUMBAI: In a setback to Sanofi SA, the Bombay High Court has dismissed the plea filed by the French pharmaceutical major saying 'superior' packaging cannot be the argument for higher pricing of Drugs. The court order also clarified that fixing the prices of Drugs in the country will remain in the domain of the National Pharmaceutical Pricing Authority. In its argument, the pharmaceutical company had said it had relied...
More »Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced Drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable Drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »
